TRVI Stock Forecast & Price Target

Trevi Therapeutics Inc. is concentrating on the advancement of Haduvio, an investigational therapy that has demonstrated a significant placebo-adjusted cough reduction of approximately 56% in its Phase 2a RIVER trial, outperforming a competitor's trial. The company's financial position is improving, as evidenced by a narrowed fourth-quarter net loss of $8.3 million, which reflects reduced clinical development costs and increased interest income, while the balance sheet is robust enough to support multiple ongoing clinical trials without immediate financing pressures. Furthermore, recent regulatory alignment with the FDA provides a clear pathway for initiating two pivotal Phase 3 trials for Haduvio in chronic cough related to idiopathic pulmonary fibrosis, establishing a strategic foothold in a market that could potentially see GSK's involvement, thereby enhancing the commercial prospects of the treatment.

Trevi Therapeutics Inc is facing significant financial challenges, as it continues to incur substantial and rising operating expenses related to the clinical development of its investigational therapy, Haduvio. The company reported a net loss of $42.8 million for FY2025, with a fourth-quarter loss of $8.3 million, indicating ongoing financial strain in a lengthy development process. Additionally, while Trevi ended 2025 with $188.3 million in cash, the decreased research and development spending and increased general and administrative costs highlight an imbalance that could impede future operational efficiency and financial stability.